Introduction
============

Cone dystrophy (COD) and cone-rod dystrophy (CORD) are retinal diseases that can be inherited as dominant, recessive, or X-linked traits \[[@r1]\] but are mainly acquired through autosomal dominant (ad) inheritance. They are characterized by damage to vision, abnormal color vision, and varying degrees of nystagmus and photophobia in the early stage, followed by peripheral visual field loss and even blindness \[[@r1]\]. CORD involves progressive loss of cone photoreceptor function followed by gradual loss of rod cell function, and it is usually accompanied by retinal degeneration \[[@r1]\]. However, in hereditary progressive COD, only the cone function is impaired, with retinal degeneration limited to the central retina. Clinical phenotypes of COD have significant heterogeneity, so the performance of each patient in the same family can range from photoaversion to cone dystrophy.

Ten disease-causing genes (*AIPL1*-gene ID: 23746; OMIM: [604392](https://www.ncbi.nlm.nih.gov/omim/?term=604392); *CRX*-gene ID:1406; OMIM: [602225](https://www.ncbi.nlm.nih.gov/omim/?term=602225); *GUCA1A*-gene ID: 2978; OMIM: [600364](https://www.ncbi.nlm.nih.gov/omim/?term=600364); *GUCY2D*-gene ID: 3000; OMIM: [600179](https://www.ncbi.nlm.nih.gov/omim/?term=600179); *PITPNM3*-gene ID: 83394; OMIM: [608921](https://www.ncbi.nlm.nih.gov/omim/?term=608921); *PROM1*-gene ID: 8842; OMIM: [604365](https://www.ncbi.nlm.nih.gov/omim/?term=604365); *PRPH2*-gene ID: 83394; OMIM: [608921](https://www.ncbi.nlm.nih.gov/omim/?term=608921); *RIMS1-*gene ID: 22999; OMIM: [606629](https://www.ncbi.nlm.nih.gov/omim/?term=606629); *SEMA4A*-gene ID: 64218; OMIM: [607292](https://www.ncbi.nlm.nih.gov/omim/?term=607292), and *UNC119*-gene ID: 9094; OMIM: [604011](https://www.ncbi.nlm.nih.gov/omim/?term=604011)) and four loci (*CORD4*-gene ID: 9094; OMIM: [604011](https://www.ncbi.nlm.nih.gov/omim/?term=604011);

*CORD12-*gene ID: 8842; OMIM: [604365](https://www.ncbi.nlm.nih.gov/omim/?term=604365); *CORD17-*gene ID: 101409267; OMIM: [615163](https://www.ncbi.nlm.nih.gov/omim/?term=615163), and *RCD1*-gene ID: 5953; OMIM: [180020](https://www.ncbi.nlm.nih.gov/omim/?term=180020)) with unidentified genes have been found in adCOD and adCORD ([RetNet](https://sph.uth.edu/retnet/)). One of the most representative dominant CORD and COD genes is *guanylate cyclase activator A1A* (*GUCA1A*-gene ID: 2978; OMIM: [600364](https://www.ncbi.nlm.nih.gov/omim/?term=600364)), encoding guanylate cyclase activating protein 1 (GCAP1) \[[@r2]\]. *GUCA1A* is located at 6p21.1 \[[@r3]\], and GCAP1 is expressed in the rods and cones as a member of the neuronal calcium sensor family of proteins \[[@r4]\]. This protein is essential for light transduction regulation and confers retinal photoreceptor cells with Ca^2+^ sensitivity to retGC1 activity \[[@r5],[@r6]\].

Mutations in *GCAP1* disrupt calcium binding in GCAP1 or affect GCAP1/retGC1 interaction \[[@r7]\], thus reducing the Ca^2+^-dependent inhibition of GCAP1, and leading to increased retGC1 activity and levels of intracellular cyclic guanosine monophosphate (cGMP) \[[@r8],[@r9]\]. Excessive levels of cGMP have been shown to cause retinal degeneration \[[@r10],[@r11]\].

In recent years, 21 mutations in *GUCA1A* have been identified in patients with vision-threatening retinal diseases \[[@r10],[@r12]-[@r18]\], including COD, CORD, macular dystrophy (MD), and central areolar choroidal dystrophy (CACD). Nine missense mutations in *GUCA1A* have been found in COD ([Table 1](#t1){ref-type="table"}). This study illustrates a novel missense mutation in *GUCA1A* (c.431A\>G, p.D144G, exon 5) in four generations of a family with adCOD. With functional prediction and analysis, we identified the pathogenic effect of GCAP1-D144G, which can lead to increased retGC1 activity and result in persistently high levels of cGMP. This may also represent a possible mechanism for the formation of adCOD.

###### List of known and novel mutations of *GUCA1A* gene.

  Nucleotide change   protein change         Region                    Type           PolyPhen2   SIFT   PROVEAN   Mutation taster   Diagnosis
  ------------------- ---------------------- ------------------------- -------------- ----------- ------ --------- ----------------- ------------
  c.149C\>T           p.Pro50Leu             EF1-EF2 link              Missense       BEN         DEL    DEL       DIS               COD, CORD
  c.250C\>T           p.Leu84Phe             EF2helix F                Missense       PRO         TOL    DEL       DIS               MD
  c.256G\>C           p.Gly86Arg             EF2-EF3 hinge             Missense       PRO         DEL    DEL       DIS               MD
  c.265G\>A           p.Glu89Lys             EF2-EF3 link              Missense       POS         DEL    DEL       DIS               COD
  c.296A\>G           p.Tyr99Cys             EF3 helix E               Missense       PRO         DEL    DEL       DIS               COD
  c.299A\>G           p.Asp100Gly            EF3 loop, Ca^2+^binding   Missense       PRO         DEL    DEL       DIS               CORD, MD
  c.300T\>A           p.Asp100Glu            EF3 loop, Ca^2+^binding   Missense       PRO         DEL    DEL       DIS               COD, CORD
  c.302_304delTAG     p.Val101del            EF3 loop                  Indel          N.A         N.A.   DEL       DIS               MD
  c.304G\>C           p.Asp102His            EF3 loop, Ca^2+^binding   Missense       PRO         DEL    DEL       DIS               CORD
  c.312C\>A           p.Asn104Lys            EF3 loop, Ca^2+^binding   Missense       PRO         DEL    DEL       DIS               COD
  c.320T\>C           p.Ile107Thr            EF3 loop                  Missense       PRO         DEL    DEL       DIS               MD
  c.332A\>T           p.Glu111Val            EF3 loop, Ca^2+^binding   Missense       BEN         DEL    DEL       DIS               CORD
  c.341C\>T           p.Thr114Ile            EF3 helix F               Missense       BEN         DEL    NEU       POL               P.U.
  c.359--360delTT     p.Arg120Leu            EF3 loop, Ca^2+^binding   Missense       N.A.        N.A.   NEU       DIS               CACD
  c.428delTinsACAC    p.Ile143delinsAsnThr   EF4 helix E               Delins/Indel   N.A.        N.A.   DEL       POL               COD
  c.431A\>G           p.Asp144Gly            EF4 loop, Ca^2+^binding   Missense       PRO         DEL    DEL       DIS               This study
  c.444T\>A           p.Asp148Glu            EF4 loop, Ca^2+^binding   Missense       PRO         TOL    DEL       DIS               COD
  c.451C\>T           p.Leu151Phe            EF4 loop Ca^2+^binding    Missense       PRO         DEL    DEL       DIS               COD, CORD
  c.464A\>G           p.Glu151Gly            EF4 loop, Ca^2+^binding   Missense       PRO         DEL    DEL       DIS               COD
  c.464A\>C           p.Glu155Ala            EF4 loop, Ca^2+^binding   Missense       PRO         DEL    DEL       DIS               COD
  c.476G\>T           p.Gly159Val            EF4 helix F               Missense       PRO         DEL    DEL       DIS               COD, CORD
  c.526C\>T           p.Leu176Phe            Carboxy terminal          Missense       PRO         TOL    NEU       DIS               MD

EF, helix E-loop-helix F; Ca^2+^-binding, Ca^2+^-binding domain; PRO for probably damaging; POS for possibly damaging; BEN for benign; DEL for deleterious; TOL for tolerated; N.A. for not applicable; DEL for deleterious; NEU for neutral; DIS for disease causing; POL for polymorphism; P.U. for Pathogenetic unknow.

Methods
=======

Participants and clinical examination
-------------------------------------

Four generations of a family with adCOD were recruited at theQingdao eye hospital of Shandong Eye Institute (Qingdao,China). There were 16 members in the family (7 affected, 9 unaffected; 7 males, 9 females). The 7 affected patients included (I:I, male, 82 years; II:2, female, 63 years; II:3, male, 61 years; III:2, female, 38 years;III:3, male, 37 years; IV:2, female, 8 years; IV:3, male, 15 years).The 9 unaffected patients included (I:2, male, 70years; II:1, male, 65 years; II:4, male, 61 years; III:1, male, 39 years; III:4, male, 37 years; III:5, male, 35 years; III:6, female, 33 years; IV:1, female, 10 years; IV:4, female, 9 years).They all had no other systemic abnormalities. Two hundred individuals with no medical history associated with any ophthalmic diseases were included in the control group. All participants received a comprehensive ophthalmic examination, including measurement of visual acuity and intraocular pressure, color vision testing, fundoscopy, multifocal electroretinography, and optical coherence tomography (OCT). The study was conducted according to the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Qingdao University with informed consent from all participants. Written informed consent were obtained from all participants.

Genetic testing
---------------

Peripheral venous blood (5 ml) of the participating family members was sampled, and genomic DNA was extracted with a DNA isolation kit for mammalian blood (Tiangen, Beijing, China). Venous blood and genomic DNA samples were stored at −80 °C before use. The proband (III:2) underwent next-generation sequencing captured with 532 inherited genes related to the genetic visual system. The exon regions of these genes were particularly enriched with a biotinylated capture probe (Joy Orient Translational Medicine Research, Beijing, China). Burrows-Wheeler Aligner (BWA) software was used to perform short-read mapping and alignment, while SOAPsnp software and GATK Indel Genotype were used to test single nucleotide polymorphism (SNP) and insertion and deletion mutations, respectively. Identified mutants were filtered in databases. Sanger sequencing verified whether any remaining variants were cosegregated with the family disease phenotype. The novel mutations in *GUCA1A* were also genotyped with Sanger sequencing in the 200 normal control subjects. The possible pathogenicity of the mutations was predicted using the Sorting Intolerant from Tolerant ([SIFT](https://sift.bii.a-star.edu.sg)) algorithm, Polymorphism Phenotyping v2 ([PolyPhen-2](http://genetics.bwh.harvard.edu/pph2/)), Protein Variation Effect Analyzer ([PROVEAN](provean.jcvi.org/seq_submit.php)), and [MutationTaster](http://www.mutationtaster.org).

Sequence alignment and structure modeling of GCAP1
--------------------------------------------------

The human GCAP1 protein ([NP_000400.2](https://www.ncbi.nlm.nih.gov/protein/NP_000400.2)) sequence was aligned for analysis of the conservation of the mutated residues with the sequences of the following orthologous proteins: *Bos* *taurus* ([NP_776971](https://www.ncbi.nlm.nih.gov/protein/NP_776971)), *Danio* *rerio* ([NP_571945](https://www.ncbi.nlm.nih.gov/protein/NP_571945)), *Gallus* *gallus* ([NP_989651](https://www.ncbi.nlm.nih.gov/protein/NP_989651)), *Mus musculus* ([NP_032215](https://www.ncbi.nlm.nih.gov/protein/NP_032215)), *Rattus* *norvegicus* ([NP_001100357](https://www.ncbi.nlm.nih.gov/protein/NP_001100357)), *Takifugu* *rubripes* ([NP_001027790](https://www.ncbi.nlm.nih.gov/protein/NP_001027790)), and *Xenopus* *tropicalis* ([NP_001096291](https://www.ncbi.nlm.nih.gov/protein/NP_001096291)). Multiple alignments were made using ClustalX2 software. The SWISS-MODEL was used to model the homology structure of the GCAP1 mutant based on the chicken wild-type (WT) GCAP1 (Protein Data Bank identifier: 2r2i), and three-dimensional (3D) models of proteins were constructed via PyMol software.

Preparation of plasmids and cloning, protein expression, and purification
-------------------------------------------------------------------------

Glutathione-S-transferase (GST)-tagged GCAP1 (GST-GCAP1) was generated via PCR amplification of human GCAP1 cDNA and inserted into pGEX-4T-1. After an initial denaturation step at 94 °C for 3 min, 35 PCRcycles (denaturation: 94 °C, 40 s; annealing: 52 °C, 40 s; extension: 72 °C, 2 min) and a final extension step at 72°C for 10 min were performed. For FLAG-tagging, full-length GCAP1 was inserted into pcDNA3.1. For green fluorescent protein (GFP)-tagging, full-length retGC1 was inserted into the pEGFP-N1 vector to obtain the recombinant plasmid pEGFP-retGC1. GCAP1-D144G was created with PCR amplification and confirmed with sequencing. The methods for expressing fusion proteins were the same as previously described \[[@r19]\].

Fusion proteins GCAP1-WT and GCAP1-D144G were expressed from the PGEX-4T-1 vector in BL21 (DE3) competent *E. coli* cells. The overexpressed protein was subsequently purified as described previously \[[@r20]\] with some modifications. Cells was grown in standard Luria-Bertani (LB) medium (Solarbio, Beijing, China) containing 100 µg/ml ampicillin at 1.0 l, until they reached A~600~ 0.6--0.7. After induction with 0.5 mM isopropyl β-D-thiogalactoside (IPTG) for 2 h, bacterial precipitation obtained with centrifugation at 956 ×g for 30 min at 4 °C was resuspended, and lysozyme was added into the buffer. The cells were then thawed and disrupted with ultrasonication, before 10 mg of streptomycin sulfate was added after the supernatant was centrifuged. The supernatant was centrifuged again, and 60 mg of glutathione agarose (Solarbio, Beijing, China) was added and incubated end-over-end for 2 h at 4 °C. The precipitate was washed with 30 ml of harvest buffer (1 M HEPES, 1 M NaCl, 1 mM benzamidine, and water) after 956 ×g centrifugation at 4 °C. The purity of the final purified GCAP1 protein determined with sodium dodecyl sulfate (SDS) gel electrophoresis was greater than or equal to 95%.

Cell culture and transfection
-----------------------------

Human embryonic kidney (HEK)-293 cells (Appendix 1) were grown at 37 °C in 5% CO~2~, incubated, and maintained in complete, high-glucose Dulbecco's modified Eagle's medium (HyClone, Logan, UT), which was supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. According to the manufacturer's instructions, the cells were transfected with Lipofectamine 2000 (Invitrogen, Carlsbad, CA). During the detection of protein stability, pcDNA3.1-GUCA1A-WT and pcDNA3.1-GUCA1A-D144G were transfected into the HEK-293 cells, and the protein supernatants were extracted for western blotting at 24, 48, and 72 h after transfection. To express retGC1 for the functional assay in vitro, the HEK-293 cells were transiently transfected with a 30 μg of pEGFP-retGC1 plasmid using Lipofectamine 2000 in a 90-mm culture dish according to the manufacturer's instructions.

Coimmunoprecipitation and western blotting
------------------------------------------

Coimmunoprecipitation (co-IP) and western blotting were performed as previously reported \[[@r19]\]. Briefly, HEK-293 cells were transfected with equal amounts of pcDNA3.1-GUCA1A-WT or pcDNA3.1-GUCA1A-D144G in the presence or absence of pEGFP-retGC1, followed by lysis in 1 ml of ice-cold lysis buffer containing 10 mM HEPES, 100 mM NaCl, 1 mM benzamidine, and 0.5% Triton X-100 (pH 7.4). After centrifugation, the lysates were incubated with anti-GFP antibody with protein-A/G agarose (Beyotime Biotechnology, Haimen, China) for 3 h. After being washed with cold wash buffer (10 mM HEPES, 100 mM NaCl, 0.1% Tween-20, benzamidine, and 3% bovine serum albumin \[BSA\]) three times, the immunoprecipitated proteins were eluted from the beads with SDS sample loading buffer. The co-IP assay was performed using anti-GFP affinity gel, while the bound proteins were detected with immunoblotting with anti-FLAG antibody. Then, the eluted samples were separated with SDS--polyacrylamide gel electrophoresis (PAGE), visualized with western blotting, and quantified by NIH Image 1.62. Each sample was normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Primary antibodies included anti-FLAG antibody (Proteintech Group, Chicago, IL), anti-GFP antibody (Proteintech Group), and anti-GAPDH antibody (Kangchen, Shanghai, China).

Limited protein hydrolysis of GCAP1
-----------------------------------

Limited protein hydrolysis of purified GCAP1 and GCAP1-D144G was observed in SDS--PAGE in the presence or absence of 2.5 μM Ca^2+^ as previously described \[[@r21]\]. Purified recombinant GCAP1 or GCAP1-D144G was incubated with trypsin at 30 °C, and the digest was analyzed with SDS-PAGE at 0, 5, 10, and 20 min.

Immunofluorescence staining
---------------------------

The HEK-293 cells were cotransfected with pEGFP-retGC1 and pcDNA3.1-GUCA1A-WT/D144G plasmid as previously reported. The following is a supplement to the protocol'sdetails. PEGFP-retGC1 and pcDNA3.1-GUCA1A-WT / D144G plasmids were co-transfected into HEK-293 cells with a GCAP1: retGC1 plasmid ratio of 1: 0.5. According to the reagent manufacturer\'s instructions, the cells were transfected with Lipofectamine 2000 The slides of the cells cultured in the standard glass coverslip chambers (four 2 cm^2^ chambers per slide) were washed twice with PBS (1X; 8 mM Na~2~HPO~4~, 137 mM NaCl, 2mM KH~2~PO~4~, 2.6 mM, KCL, pH 7.2), fixed with 4% paraformaldehyde for 15 min, and washed again following permeation with 0.2% Triton X-100. After being blocked overnight with 5% normal goat serum, the samples were incubated with anti-FLAG antibody at 37 °C for 1 h, washed, and stained with a fluorescein-conjugated second antibody (donkey anti-rabbit immunoglobulin (IgG; H^+^L; Life Technologies, Carlsbad, CA) at 37 °C for 30 min. The cell nucleus was counterstained with 4', 6-diamidino-2-phenylindole (DAPI) for 5 min and then washed as mentioned above. Cells were observed using a fluorescence microscope (CKX53, Olympus, Tokyo, Japan).

ELISA
-----

pcDNA3.1-GUCA1A-WT and pcDNA3.1-GUCA1A-D144G were transfected into the HEK-293 cells. The cell pellets were divided into groups of EGTA (1 μM EGTA) and Ca^2+^ (2.5 μM Ca^2+^) after they were homogenized in 300 µl of lysis buffer with the added protease inhibitor cocktail.

Human retGC1 was expressed in the HEK-293 cells, and the washed cell membranes were prepared as previously described \[[@r22]\]. Briefly, the membranes containing equal amounts of total protein were resuspended in GC buffer (100 mM KCl, 50 mM Mops, 7 mM 2-mercaptoethanol, 8 mM NaCl, 10 mM MgCl2, 1 mM EGTA). Cell membranes were incubated with equal amounts of purified GCAP1-WT/D144G proteins, and the cGMP concentrations were measured at different free Ca^2+^ levels using a Ca^2+^-EGTA buffer system (1 μM EGTA or 2.5 μM Ca^2+^).

Protein concentrations were standardized by extracting the protein and using a bicinchoninic acid (BCA) protein assay kit. Human cGMP competition enzyme-linked immunosorbent assay (ELISA; human cGMP ELISA Kit; Mlbio, Shanghai, China) was used to determine the cGMP levels following the manufacturer's instructions.

Statistical analysis
--------------------

SPSS 19.0 was used for statistical analysis, and quantitative data were analyzed by using the Student *t* test to compare groups. The data are presented as the mean ± standard deviation (SD), and a p value of less than 0.05 was considered statistically significant.

Results
=======

Clinical assessment and findings
--------------------------------

Ophthalmic examination confirmed that seven of 16 members across the four generations of the sampled family were affected by adCOD ([Figure 1](#f1){ref-type="fig"}). All patients had similar features, including progressive vision loss, photophobia, nystagmus, color vision impairment, and visual field impairment. The proband (III:2) was a female patient aged 43 years at the time of observation. Her best corrected visual acuity was oculus dexter (OD) 0.1 and oculus sinister (OS) 0.05. The fundus appearance ([Figure 2A,B](#f2){ref-type="fig"}) and macular OCT ([Figure 2C](#f2){ref-type="fig"}) were consistent with the diagnosis. Patient IV:3 was first seen at age 16. His best corrected visual acuity was OD 0.5 and OS 0.4. His fundoscopy ([Figure 3A,B](#f3){ref-type="fig"}) and macular OCT ([Figure 3C](#f3){ref-type="fig"}) results were also in accordance with the diagnosis. For IV:3, the multifocal electroretinography examination showed that the amplitude density of the left eye's macular area was significantly reduced ([Figure 3D](#f3){ref-type="fig"}). Humphrey visual field examination showed that the visual fields of both eyes were defected to different degrees ([Figure 3E](#f3){ref-type="fig"}).

![Pedigree of a Chinese family with COD. Squares and circles indicate males and females, respectively, and the filled symbols represent affected members. Deceased individuals are indicated with slashes (/). The arrow indicates the proband.](mv-v25-921-f1){#f1}

![Phenotypic appearance of the COD proband (III:2). **A**: The fundus photograph shows that III:2 had oval lesions in the macular area and discoid depigmentation. The foveal reflex disappeared in both eyes. The macular area of her left eye is blue-gray with golden foil reflections, and the boundary is clear. There is irregular, patchy hyperplasia in her left eye. **B**: The infrared fundus photograph demonstrates the depigmentation zone in the macular area and slightly higher reflection in the mid-peripheral area. **C**: On the macular optical coherence tomography (OCT) images, the foveal centralis of both eyes is thin, and the ellipsoid and chimera bands are absent. Subepithelial hyper-reflexes are deposited, and choroidal capillary layer reflexes are enhanced in the foveal centralis. OD (right eye), OS (left eye).](mv-v25-921-f2){#f2}

![Phenotypic appearance of patient IV:3. **A**: Both eyes have a clear optic disc boundary and a slightly dark macular area. The left eye shows diffuse depigmentation (window-like defect) and generally normal retinal vessels, with no bleeding or exudation in the retina. **B**: A slightly high reflex zone is visible on the temporal lateral of the central macular fovea in the left eye on infrared fundus photography. **C**: The macular optical coherence tomography (OCT) examination shows that the band imaging of both eyes is slightly blurred. **D**: Multifocal electroretinography indicates that the amplitude density of the macular area in the left eye is significantly reduced. **E**: The Humphrey visual field examination disclosed that the visual field of both eyes has defects in different degrees.](mv-v25-921-f3){#f3}

Identification of *GUCA1A* as a candidate gene
----------------------------------------------

The proband (III:2) was genetically tested with exome sequencing of a set of candidate genes. The average sequence depth was 58.34, and 72.21% of the exon sequences were sequenced at least ten times. Sixty-two non-synonymous SNPs, two splicing sites, and one indel were selected according to the recommended filtering criteria. In exon 5 of *GUCA1A*, only a novel missense mutation (c.431A \> G, p.D144G) was cosegregated in the family ([Figure 4A](#f4){ref-type="fig"} and [Table 1](#t1){ref-type="table"}). This mutation was not found in the 200 control individuals. PolyPhen-2 and SIFT predicted that the D144G missense mutation would lead to harmful changes in the function of *GUCA1A* ([Table 1](#t1){ref-type="table"}).

![Location and structure of the D144G missense mutation. **A**: Sequence chromatograms of the detected mutations in *GUCA1A*. The top chromatogram represents the sequence of a healthy family member (III:5). The middle (III:2) and bottom (IV:3) chromatograms show a missense mutant sequence, which is A--G transversion in exon 5 of *GUCA1A*. The arrow indicates the location of the mutation. **B**: Orthologous protein sequence alignment of GCAP1 from multiple species. The 144 GLY of the EF4 loop region replaced the negatively charged ASP residue (arrows). Conservative residues are printed on a black background. The 12-amino-acid loop of the EF4-hand domains of the protein are underlined, and the other six known mutations are indicated with an asterisk. C: The structure of the GCAP1 three-dimensional homologous model. EF1 is slate, EF2 is yellow, EF3 is green, and EF4 is orange. The N- and C-terminal helixes are gray white and pale cyan, while the loop is deep pink. Mutated amino acids are indicated in red, and Ca^2+^ ions are shown as red spheres. Residue D144 is shown as sticks, and 144 GLY is magenta and also shown as sticks. P50L is located in the EF1-EF2 link; Y99C, D100E, and E111V are located in EF3; and E155G, G159V, and D144G are located in EF4. **D**: Details of the region surrounding D144G. Hydrophobic residues showing persistent interactions with D144G are labeled as sticks. The hydrogen bonds are highlighted in green. The hydrogen bonds between residue 144 and residue Phe140 or Gly147 were eliminated upon changing from the wild-type ASP to mutant GLY.](mv-v25-921-f4){#f4}

D144 located in the EF4 hand loop was involved in calcium binding ([Figure 4B,C](#f4){ref-type="fig"}). Multiple alignments of D144 of the GCAP1 protein from different species revealed 100% identification, which suggested it was highly conserved during evolution ([Figure 4B](#f4){ref-type="fig"}). The homology structure of GCAP1-D144G ([Figure 4C](#f4){ref-type="fig"}) showed that the hydrogen bonds between residue 144 and residue Phe140 or Gly147 in GCAP1 were eliminated due to substitution from Aspartyl (Asp) to Glycine (Gly) ([Figure 4D](#f4){ref-type="fig"}).

Regulation of retGC1 by GCAP1-WT and GCAP1-D144G
------------------------------------------------

We assayed the ability of GCAP1-WT and GCAP1-D144G to regulate retGC1in vitro ([Figure 5A](#f5){ref-type="fig"}). The concentration of cGMP in the Ca^2+^ group became lower than that in the EGTA group after induction by GCAP1-WT (p\<0.05), whereas it was higher than that in the EGTA group due to induction by GCAP1-D144G (p\<0.01). GCAP1-D144G caused a statistically significant increase in the cGMP concentration compared to GCAP1-WT (p\<0.01) in the presence of Ca^2+^. The same experimental result was also found in vitro ([Figure 5B](#f5){ref-type="fig"}). GCAP1-D144G led to a higher increase of cGMP synthesis than did GCAP1-WT (p\<0.01; [Figure 5B](#f5){ref-type="fig"}).

![The levels of cGMP induced by retGC1 are regulated by GCAP1-WT/D144G in vitro. **A**: The levels of cyclic guanosine monophosphate (cGMP) induced by retGC1 in the human embryonic kidney (HEK)-293 cells are measured in the presence of GCAP1-WT/D144G. The free Ca^2+^ concentration is 2.5 μM. The mock-transfected group was used as control. **B**: The levels of cGMP stimulated by transfected retGC1 in the HEK-293 cells were regulated by purification of GCAP1-WT/D144G. The free Ca^2+^ concentration was 2.5 μM. The operation was repeated three times. Error bars were standard deviation.](mv-v25-921-f5){#f5}

Biochemical analysis of GCAP1-D144G
-----------------------------------

To detect the effect of GCAP1-D144G on the protein structure, limited protein hydrolysis experiments were performed. In the absence of Ca^2+^, GCAP1-WT was readily susceptible to proteolysis after 5 min of exposure to trypsin, while GCAP1-D144G was completely digested ([Figure 6A](#f6){ref-type="fig"}), indicating the open conformation of GCAP1-WT and D144G. Furthermore, the tight core of GCAP1-WT remained after 20 min of digestion in the presence of Ca^2+^. Under the same condition, GCAP1-D144G was more susceptible to hydrolysis after 20 min of exposure to trypsin ([Figure 6A](#f6){ref-type="fig"}). It indicated that GCAP1-WT exhibited a tighter conformation than D144G in the presence of Ca^2+^.

![Biochemical analysis of GCAP1-D144G. **A**: Limited proteolysis of GCAP1-wild type (WT) and GCAP1-D144G by trypsin in the presence and absence of Ca^2+^. Digestions were performed at 30 °C for 0, 5, 10, and 20 min. **B**: Electrophoresis shift assay of GCAP1-WT and GCAP1-D144G in the presence of 2.5 μM Ca^2+^. **C**: The expression level and stability of GCAP1-WT and GCAP1-D144G in human embryonic kidney (HEK)-293 cells. GCAP1-WT and GCAP1-D144G were transfected into the HEK-293 cells. The proteins were detected using anti-FLAG antibody at 24, 48, and 72 h. The bars and error bars represent the mean ± standard deviation (SD) of three independent experiments, and the values within each experiment were normalized to those of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). CONT, control.](mv-v25-921-f6){#f6}

The electrophoresis shift assay showed that GCAP1-WT exhibited a higher degree of electrophoretic mobility than GCAP1-D144G in the presence of Ca^2+^ ([Figure 6B](#f6){ref-type="fig"}), which was typical for calmodulin-like Ca^2+^ binding proteins (the faster-moving, inactive form). However, the same experiment with GCAP1-D144G highlighted slower mobility during the electrophoresis shift assay in the presence of Ca^2+^, indicating that the Ca^2+^ induction of the mutant conformation was less pronounced, indicating a significantly decreased affinity for Ca^2+^.

The expression levels and stability of GCAP1 in HEK-293 cells were analyzed with western blotting. With the extension of the transfection time, the GCAP1-WT protein levels remained almost unchanged ([Figure 6C](#f6){ref-type="fig"}). However, the levels of GCAP1-D144G decreased statistically significantly in a time-dependent manner ([Figure 6C](#f6){ref-type="fig"}). Even after 72 h of transfection, the expression levels of GCAP1-D144G were statistically significantly lower than those of GCAP1-WT (p\<0.01; [Figure 6C](#f6){ref-type="fig"}).

Combination and colocalization of retGC1 and GCAP1-WT or GCAP1-D144G
--------------------------------------------------------------------

To determine whether GCAP1-WT/D144G was colocalized with retGC1, the HEK-293 cells were cotransfected with FLAG-GCAP1-WT/D144G and GFP-retGC1. GCAP1-WT and GCAP1-D144G exhibited a similar membrane distribution, predominantly endoplasmic reticulum membranes, when they were coexpressed with retGC1 ([Figure 7A](#f7){ref-type="fig"}).

![Cellular localization and combination of GCAP1 and retGC1. **A**: FLAG-GCAP1-wild type (WT)/D144G (red) and green fluorescent protein (GFP)-retGC1 (green) were coexpressed in human embryonic kidney (HEK)-293 cells. **B**: Interactions between FLAG-GCAP1-WT/D144G and GFP-retGC1 were detected with the co-IP assay. HEK-293 cells were cotransfected with FLAG-tagged GCAP1-WT or FLAG-GCAP1-D144G in the presence or absence of GFP-tagged retGC1. **A**: The precipitated complexes were probed with the FLAG antibody to detect FLAG-GCAP1-WT/D144G. The cell lysates were probed with the anti-GFP antibody and anti-FLAG antibody in western blotting for analysis of GFP-retGC1 expression (**B**) and FLAG-GCAP1-WT/D144G (**C**), respectively. WB, western blotting. IP, immunoprecipitation. The data are representative of three independent experiments.](mv-v25-921-f7){#f7}

To test the ability of GCAP1-WT/D144G to bind to retGC1, co-IP experiments were performed. As shown in [Figure 7B](#f7){ref-type="fig"}, the FLAG-GCAP1 protein was not detectable in the immunoprecipitated complex in the cells transfected with FLAG-GCAP1-WT or FLAG-GCAP1-D144G alone. In the cells cotransfected with FLAG-GCAP1 and GFP-retGC1, however, the FLAG-GCAP1 protein could be detected in its immunoprecipitated complex. GCAP1-D144G enhanced the association of GCAP1 with retGC1 in HEK-293 cells.

Discussion
==========

Mutations in *GUCA1A* have been found in CORD, which is a blinding eye disease affecting 1/30,000 to 1/40,000 individuals \[[@r1]\]. Some common features of retinal dystrophies associated with these mutations have been identified \[[@r10],[@r12]-[@r14]\]. However, the molecular characteristics do not necessarily relate to similar clinical phenotypes \[[@r10]\]. Therefore, the molecular mechanism and function of each mutation must be investigated.

GCAP1 contains four EF hand motifs (EF1--4), with each containing a helix--loop--helix conformation \[[@r23]\]. EF1 and EF2 form the N-terminal domain, whereas EF3 and EF4 are contained in the C-terminal region \[[@r24]\]. EF1 is modified for the interface with guanylate cyclases (GCs) \[[@r25]\], while EF2, EF3, and EF4 bind to Ca^2+^ \[[@r2]\]. Among the 21 previously reported mutations in *GUCA1A,* two were deletion mutations, and the others were missense mutations, including nine missense mutations found in patients with COD. This study recruited four generations of a family with adCOD exhibiting clinical phenotypes of adCOD, such as progressive vision loss, abnormalities of color vision, and nystagmus. Genetic tests detected a novel mutation in *GUCA1A* (c.431A\>G, p.D144G, exon 5) in the family. The characteristics of the clinical phenotypes, their molecular features, and specific functions of the mutant protein were subsequently evaluated.

Biochemically, most mutations in *GCAP1* are located in the EF hand regions. Ile143AsnThr \[[@r26]\], Leu151Phe \[[@r27]-[@r29]\], Glu155Gly \[[@r11]\], and Gly159Val \[[@r30]\], which are located in EF4, disrupt calcium binding in GCAP1 or affect GCAP1/retGC1 interactions \[[@r31]\]. Thus, reducing Ca^2+^-dependent inhibition of GCAP1 could promote the constitutive activity of retGC1 and increase the intracellular cGMP levels \[[@r8],[@r9],[@r32]\], ultimately leading to photoreceptor death. The novel missense mutation (p.D144G) found in this research was also located in EF4. Biochemical results disclosed that the substitution of ASP with 144 GLY may partially impair GC1 inhibition, which constitutively activated retGC1 at the normal, dark Ca^2+^ levels and generated a continuous increase in the intracellular cGMP levels. The calcium sensitivity effect of mutations in reducing GC stimulation has also been seen in Y99C \[[@r9]\], N104K \[[@r33]\], E111V \[[@r10]\], T114I \[[@r26]\], 143NT \[[@r26]\], L151F \[[@r27]-[@r29]\], and E155G \[[@r11]\].

Sequence analysis showed that the 144 ASP was highly conserved. It was necessary for the correct coordination of Ca^2+^ in the EF4 loop with high affinity sites. The SWISS-MODEL was used to model the homology structure of GCAP1-D144G on the basis of GCAP1. It was shown that the hydrogen bonds between residue 144 and residue PHE140 or GLY147 in GCAP1-WT were eliminated due to the substitution of ASP with 144 GLY. These hydrogen bonds appeared to be important for the tertiary structure of the protein because they linked the EF3 helix and the EF4 loop. Therefore, GCAP1-D144G may result in the loss of hydrogen bonds in the protein, interfering with correct GCAP1 folding.

Limited protein hydrolysis experiments indicated that GCAP1-D144G was more susceptible to proteolysis. GCAP1-D144G cannot presume a compact Ca^2+^-bound conformation, which was necessary for the inactivity in dark Ca^2+^. The same effects have been observed in GCAP1-N104K \[[@r33]\], L151F \[[@r27],[@r28]\], and I143NT \[[@r26]\]. GCAP1-N104K, located in the EF3 loop, was replaced by positive-charge amino acids and destroyed the binding of the EF3 hand to Ca^2+^ \[[@r33]\]. GCAP1-L151F was in the β-folding of the EF4 hand, and its molecular dynamic confirmed that changes in the mutant structure affected the binding of Ca^2+^ in the EF4 and EF2 hands \[[@r28]\]. GCAP1-I143NT was located on the EF4 hand helix. The substitution of Ile143 with two polar residues changed the orientation of the N-terminal α-helix, which reduced the affinity of the EF hands to Ca^2+^ \[[@r26]\].

An electrophoretic shift assay showed that Ca^2+^ binding resulted in lower electrophoretic mobility of GCAP1-D144G in the presence of 2.5 μM Ca^2+^ while GCAP1-WT showed higher mobility. This suggested that the affinity of the mutant for Ca^2+^ was significantly reduced. With respect to the protein stability, the expression levels of GCAP1-D144G significantly decreased as the transfection time was prolonged. The expression levels of the WT protein were almost identical, indicating a decrease in the stability of the mutant protein. Similarly, GCAP1-P50L showed decreased thermal stability \[[@r34]\]. These biochemical results illustrated that the *GCAP1*-D144G mutation could prevent proteins from folding into compact structures.

GCAP1 and retGC1 may control the recovery of light response in the photoreceptors of vertebrates through their molecular interactions and retGC1 in rods involved in regulating cGMP synthesis by negative calcium feedback \[[@r35]\]. Studies have shown that mutations in *GCAP1* or *retGC1* could alter the Ca^2+^ sensitivity of cGMP synthesis or affect the GCAP1/retGC1 interaction \[[@r7],[@r8],[@r22],[@r30],[@r36],[@r37]\]. Therefore, even at higher calcium concentrations, mutations in *GCAP1* can stimulate retGC1 \[[@r38]\], and ultimately, lead to degeneration and death of photoreceptors \[[@r10],[@r11],[@r13]\]. However, the mechanism by which mutations affect the GCAP1/retGC1 interaction is complex and difficult to understand \[[@r35]\]. GCAP1 activation of retGC1 may be performed either by direct binding or by indirect interaction \[[@r39]\]. Indirect interaction is consistent with the experimental results of previous studies on the binding of Ca^2+^- and Mg^2+^-saturated forms of retGC1 \[[@r40]-[@r42]\]. The conversion from activator to inhibitor status by Ca^2+^ bound to EF4 in GCAP1 is a major determinant \[[@r43]\].

It was found that GCAP1-D144G not only displayed colocalization with retGC1 in the HEK-293 cells ([Figure 7A](#f7){ref-type="fig"}) but also combined more retGC1 in the HEK-293 cells ([Figure 7B](#f7){ref-type="fig"}). However, mutations in different parts of *GCAP1* disrupted the colocalization of GCAP1/retGC1, allowing most of the GCAP1 fluorescence to be evenly distributed across the cytoplasm and nucleoplasm \[[@r39]\]. We observed only the changes in colocalization caused by the mutation. The specific mechanism must be further explored. In addition, metal ligand binding in EF4 has been reported to have no significant effect on GCAP1 association with the cyclase \[[@r44]\]. The areas of GCAP controlling its ability to activate retGC1 are the interface between EF1, EF2, EF3, and the adjacent C-terminal region of EF4 \[[@r45],[@r46]\]. EF1 has evolved in GCAPs to become the main part of the target-binding interface \[[@r39],[@r40]\]. Moreover, EF2 and EF3 can be connected to retGC1 through the combination of Ca^2+^ or Mg^2+^ \[[@r44]\]. Therefore, it is suspected that the binding of GCAP1-D144G to retGC1 may strongly affect the indirect interaction or that the structure of EF1 can be remotely affected by Ca^2+^ binding on the EF4 hand.

The process and mechanism of the interaction between GCAP1 and retGC1 after point mutation, as well as the changes in key residues and conformations involved, require further investigation. Based on the genetic testing and functional analyses, we concluded that the novel GCAP1-D144G mutation affected Ca^2+^ sensitivity and the constitutive activation of retGC1 at high Ca^2+^ levels, resulting in increased intracellular cGMP concentrations, and ultimately, likely adCOD. These findings help to introduce the diversity of phenotypes, providing guidance for clinical assessment and treatment of adCOD.
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